ATLANTA, GA – – (Globe Newswire – September 12, 2023) – – Holzer & Holzer, LLC is investigating whether Acelyrin, Inc. (“Acelyrin” or “the Company”) (NASDAQ: SLRN) complied with federal securities laws.  On September 11, 2023, Acelyrin announced top-line results from a clinical trial of izokibep, revealing that the drug failed to meet the primary endpoint of showing statistically significant reduction in abscesses and inflammatory nodules compared to patients receiving a placebo. The Company attributed the results to patient discontinuations and placebo responses. Following this news, the price of the Company’s stock dropped.

If you purchased Acelyrin stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at or Joshua Karr, Esq. at, call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share